Global Vaccine Market Analysis & Forecast (2018-2028): A $103.57 Billion Opportunity, Growing at a CAGR of 11.02%

Dublin, Dec. 10, 2018 (GLOBE NEWSWIRE) -- The "Global Vaccine Market: Focus on Product Type (Next-Generation Vaccine), Route of Administration, Disease Type, 22 Countries Mapping, and Competitive Landscape - Analysis and Forecast, 2018-2028" report has been added to ResearchAndMarkets.com's offering.

According to the research study conducted by the International Agency for Cancer Research, approximately 14.1 million new cancer cases were detected, and 8.2 million cancer deaths were reported in 2012. Moreover, considering the present prevalence rates, the number of cases detected are expected to grow over 21.7 million while the death counts are expected to reach 13 million.

The rise in the count of cancer cases has been significantly increasing the global economic burden and was estimated at $1.16 trillion in 2010.

The ongoing clinical trials for the development of cancer vaccines is aimed at enabling early diagnosis and treatment, thus consequentially aiding in combating cancer. Additionally, rising outbreaks of epidemic and zoonotic diseases in different parts of the globe has led to the development of preventive vaccines that helps occurrence and spread of these infections to a significant extent.

The global vaccine market is anticipated to reach $103.57 billion by 2028, witnessing a CAGR of 11.02% in the forecast period 2018-2028.

Some of the factors such as growing prominence for the rising need for immunization coverage, substantial investments made in the field of research and development of novel vaccines and technologies, growing demand for cancer vaccines, and increasing incidence of infectious diseases and cancer coupled with rising geriatric population are acting as significant factors propelling the growth of the global vaccine market.

In terms of vaccine type, the global vaccine market is dominated by subunit and conjugate vaccine. Subunit and conjugate vaccines were developed when inactivated and killed vaccines failed to show significant results in the treatment and prevention of several diseases. Subunit vaccines can comprise from one to 20 antigens or more at times. Moreover, subunit vaccines use recombinant DNA technology as well for the antigen biomolecules from microbes.

There are different types of subunit vaccines that are currently available in the market such as protein-based subunit vaccines, polysaccharide vaccines, and subunit conjugate vaccines. Furthermore, they are used in the treatment and prevention of large number of diseases such as influenza, hepatitis b, haemophilus influenza type B, pertussis, pneumococcal infections, and meningococcal diseases.

In terms of route of administration, the global vaccine market is dominated by intramuscular. In 2017, the market for intramuscular route of administration was valued $18.03 billion. Vaccines that are currently available in the market are majorly administered intramuscularly. Furthermore, this route of administration is effective for all age groups.

In terms of regional potential, North America is the leading contributor to the global vaccine market and contributed approximately 35% of the global market values in 2017. This can be attributed to high adoption rate of advanced technologies, increasing healthcare investments, presence of major manufacturers and increasing research and clinical trials by researchers and scientists for development of new vaccines across various universities in the region.

The key players who have been contributing significantly to the global vaccine market are Pfizer, Inc., Merck & Co., Inc., Emergent Biosolutions Inc., Abbott Laboratories, VBI Vaccines Inc., Madison Vaccines, Vical Inc., Inovio Pharmaceuticals Inc., GlaxoSmithKline plc, CSL Limited, AstraZeneca plc, LG Chem Ltd., Daiichi Sankyo Company, Limited, Sanofi S.A., Valneva SE, Bavarian Nordic, Sinovac Biotech Ltd., and Janssen Pharmaceutica NV, among others.

Key Topics Covered

Executive Summary

1 Market Overview
1.1 Different Types and Generation of Vaccines
1.1.1 First-generation Vaccines
1.1.1.1 Live Attenuated Vaccines
1.1.1.2 Inactivated Vaccines (Killed)
1.1.2 Second-generation Vaccines
1.1.2.1 Subunit and Conjugate Vaccines
1.1.2.2 Toxoid Vaccines
1.1.2.3 Recombinant Vaccines
1.1.3 Third-generation Vaccines
1.1.3.1 DNA Vaccines
1.2 Vaccines in a Historical Perspective
1.3 Assumptions and Limitations for Market Size Calculations
1.4 Global Vaccine Market Scenario

2 Market Dynamics
2.1 Impact Analysis
2.2 Market Drivers
2.2.1 Increasing Outbreak of Epidemic Diseases
2.2.2 Advancements in Vaccine Technologies and Emergence of Effective Vaccine Delivery System
2.2.3 Increasing Global Focus on Immunization Program
2.2.4 Use of Adjuvants in Vaccines
2.3 Market Restraints
2.3.1 Safety and Efficacy Related Issues
2.3.2 Longer Timeline for Vaccine Production and High Cost Associated with Development of Vaccine
2.4 Market Opportunities
2.4.1 Development of Personalized Vaccines
2.4.2 Implementation of Artificial Intelligence (AI) and Big Data Analytics to Improve Surveillance Capacity

3 Competitive Insights
3.1 Key Strategies and Developments
3.1.1 Product Launches and Enhancements
3.1.2 Joint Ventures, Partnerships, and Collaborations
3.1.3 Mergers and Acquisitions
3.1.4 Business Expansions
3.1.5 Others
3.2 Market Share Analysis
3.3 Industry Attractiveness
3.3.1 Bargaining Power of Suppliers
3.3.2 Bargaining Power of Buyer
3.3.3 Threat of New Entrants
3.3.4 Threat of Substitute Products
3.3.5 Intensity of Competitive Rivalry

4 Industry Insights
4.1 Introduction
4.2 Regulatory Framework
4.2.1 Legal Requirements and Framework for Vaccines in the U.S.
4.2.2 Legal Requirements and Framework for Vaccines in the Europe
4.2.3 Legal Requirements and Framework for Vaccines in the Asia-Pacific
4.3 Regulatory Scenario
4.4 Product Pipeline Analysis

5 Global Vaccine Market (by Route of Administration)
5.1 Intramuscular (IM) Vaccine
5.2 Subcutaneous Vaccine
5.3 Oral Vaccine
5.4 Intravenous (IV) Vaccine
5.5 Other Vaccines

6 Global Vaccine Market (by Type)
6.1 Subunit and Conjugate Vaccine
6.2 Live Attenuated Vaccine
6.3 Inactivated Vaccine
6.4 Recombinant Vaccine
6.5 Toxoid Vaccine
6.6 Next-generation Vaccine

7 Global Vaccine Market (by Disease Type)
7.1 Pneumococcal Disease
7.2 Diphtheria, Tetanus, and Pertussis (DTP)
7.3 Influenza
7.4 Cancer
7.5 Human Papilloma Virus (HPV)
7.6 Meningococcal Disease
7.7 Hepatitis
7.8 Measles, Mumps, and Rubella (MMR)
7.9 Rotavirus
7.10 Varicella
7.11 Other Diseases

8 Global Vaccine Market (by Region)
8.1 Overview
8.2 North America
8.3 Europe
8.4 Asia-Pacific
8.5 Latin America
8.6 Middle East and Africa

9 Company Profiles
9.1 Overview
9.2 Abbott Laboratories
9.2.1 Company Overview
9.2.2 Role of Abbott Laboratories in Global Vaccine Market
9.2.3 Financials
9.2.3.1 Key Insights on Financial Health of Company
9.2.4 SWOT Analysis9.3 AstraZeneca plc
9.4 BiondVax Pharmaceuticals Ltd.
9.5 Bavarian Nordic
9.6 CSL Limited
9.7 Daiichi Sankyo Company, Limited
9.8 Emergent BioSolutions Inc.
9.9 GlaxoSmithKline plc
9.10 Inovio Pharmaceuticals Inc.
9.11 Johnson & Johnson
9.12 Merck & Company Inc.
9.13 Madison Vaccines Incorporated
9.14 Pfizer, Inc.
9.15 Sanofi S.A.
9.16 Sinovac Biotech Ltd.
9.17 Valneva SE
9.18 VBI Vaccine Inc.

For more information about this report visit https://www.researchandmarkets.com/research/8mptvg/global_vaccine?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Press Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    Related Topics: Vaccines